Q1 adjusted net profit was at Rs 29,961 million, up 5.7 per cent YoY
Sun Pharmaceutical Industries reported financials for the first quarter ending June 30, 2025.
Highlights of Q1FY26 consolidated financials
· Gross sales at Rs 137,861 million, growth of 10.1 per cent
· India formulation sales at Rs 47,211 million, up 13.9 per cent
· US formulation sales at $ 473 million, up 1.4 per cent
· Global Innovative Medicines sales at $ 311 million, up 16.9 per cent, accounting for 19.3 per cent of Q1FY26 sales
· Emerging Markets formulation sales at $ 298 million, up 5.1 per cent
· Rest of World formulation sales at $ 219 million, up 15.5 per cent
· R&D investments at Rs 9,029 million or 6.5 per cent of sales compared to Rs 7,940 million for Q1FY25
· EBITDA at Rs 43,017 million (including other operating revenues), up 19.2 per cent, with a resulting EBITDA margin of 31.1 per cent.
· Profit before exceptional items and tax was Rs 39,908 million up 16.6per cent
· Adjusted net profit (excluding the exceptional items) for Q1FY26 was Rs 29,961 million, up 5.7 per cent. Reported net profit for Q1FY26 was Rs 22,786 million compared to Rs 28,356 million during Q1FY25
Dilip Shanghvi, CMD, Sun Pharma said, “Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The US launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business.”
